CDKN2A and atherosclerosis: However, this study alone is not sufficient to exclude the therapeutic value of targeting senescent ECs in atherosclerosis, as the p16 transcript level can be difficult to detect in single-cell RNA sequencing assays and may not acutely represent p16 protein abundance [321,322].